• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EVE 0.00% 0.1¢

EVE HEALTH GROUP LIMITED. - Announcements

EVE Health Group Limited is an Australia-based vertically integrated producer of branded... EVE Health Group Limited is an Australia-based vertically integrated producer of branded nutrition, health and wellness products. The Company’s Meluka business provides branded wellness consumer products. Its Meluka business is focused on supporting sales of its digestive health products, in particular the P3 Gut Builder. It provides probiotic supplement powder system for improved digestive health. The functional gut nutrition solution is in the form of a three-step supplement powder system, each of which contain pre, pro and postbiotics as well as selected functional superfood ingredients in an easy to consume and versatile offering. The Company also offers honey and essential oil products. Its honey products include organic raw honey and raw honey probiotic concentrate. The Company has global reach and application to various markets across Australia and New Zealand, Asia Pacific and North America.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

Filters [Clear]
  • Price Sensitive: Yes
EVE PlacementPRICE SENSITIVE26/03/19
EVE Meluka Honey Appoints OpenDNA for Chinese Market EntryPRICE SENSITIVE12/03/19
EVE Appendix 4D and Half Year ReportPRICE SENSITIVE01/03/19
EVE EVE to Acquire Remaining 50% of Meluka HealthPRICE SENSITIVE25/02/19
EVE Response to ASX Appendix 4C QueryPRICE SENSITIVE19/02/19
EVE Quarterly ReviewPRICE SENSITIVE31/01/19
EVE Meluka Honey Secures Distribution for NSW & ACTPRICE SENSITIVE14/11/18
EVE Meluka Honey Combines Anti-Microbial & Anti-Oxidant ActivityPRICE SENSITIVE08/11/18
EVE Quarterly ReviewPRICE SENSITIVE25/10/18
EVE Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE31/08/18
EVE ProspectusPRICE SENSITIVE30/08/18
EVE Quarterly ReviewPRICE SENSITIVE25/07/18
EVE Completion of THC AgreementsPRICE SENSITIVE24/07/18
EVE Omni Innovation - Update by Eagle Health on Chinese MarketPRICE SENSITIVE16/07/18
EVE Update on THC AgreementsPRICE SENSITIVE03/07/18
EVE EVE to Acquire Leading Aust Organic Tea Tree Oil ProducerPRICE SENSITIVE21/06/18
EVE Trading HaltPRICE SENSITIVE19/06/18
EVE THC: Secures Additional Site for Medicinal Cannabis GrowthPRICE SENSITIVE03/05/18
EVE Quarterly ReviewPRICE SENSITIVE30/04/18
EVE First Quarter China Sales ProgressPRICE SENSITIVE26/04/18
EVE Half Yearly Report and AccountsPRICE SENSITIVE26/02/18
EVE Meluka Consumer Products Launch at US Natural Products ExpoPRICE SENSITIVE23/02/18
EVE Rights Issue Offer DocumentPRICE SENSITIVE19/02/18
EVE ProspectusPRICE SENSITIVE06/02/18
EVE Quarterly ReviewPRICE SENSITIVE31/01/18
EVE Oversubscribed Placement & Rights Issue to Raise up to $6.3mPRICE SENSITIVE31/01/18
EVE Trading HaltPRICE SENSITIVE25/01/18
EVE Eagle Begins Shipment of Omni Innovation's Diabetes ProductPRICE SENSITIVE08/12/17
EVE Meluka Health to Develop Honey Water for Chinese MarketPRICE SENSITIVE07/12/17
EVE Eve Completes 50% Investment in Meluka HealthPRICE SENSITIVE06/12/17
EVE Response to ASX Price & Volume QueryPRICE SENSITIVE30/11/17
EVE NSW Grant for Honey Research SuccessfulPRICE SENSITIVE27/11/17
EVE ProspectusPRICE SENSITIVE22/11/17
EVE Medic Honey Produces a Hemp Seed HoneyPRICE SENSITIVE22/11/17
EVE Supply Agmt with Large Producer of Australian Organic HoneyPRICE SENSITIVE06/11/17
EVE Eagle Commences Production of Omni's Pre-Meal Diabetes ShakePRICE SENSITIVE31/10/17
EVE Appendix 4C - QuarterlyPRICE SENSITIVE20/10/17
EVE ProspectusPRICE SENSITIVE13/10/17
EVE Reinstatement to Official QuotationPRICE SENSITIVE06/10/17
EVE $1.2m Capital RaisingPRICE SENSITIVE06/10/17
EVE Voluntary SuspensionPRICE SENSITIVE27/09/17
EVE Trading HaltPRICE SENSITIVE25/09/17
EVE Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE01/09/17
EVE Revised Medical Honey Investment StructurePRICE SENSITIVE28/08/17
EVE Omni Innovation Enters Chinese Distribution AgreementPRICE SENSITIVE16/08/17
EVE Trading HaltPRICE SENSITIVE14/08/17
EVE Appendix 4C - QuarterlyPRICE SENSITIVE31/07/17
EVE ProspectusPRICE SENSITIVE04/07/17
EVE Accelerating Portfolio ProgressPRICE SENSITIVE26/06/17
EVE Southern Cross University Collaboration with Medic HoneyPRICE SENSITIVE30/05/17
EVE ProspectusPRICE SENSITIVE05/05/17
EVE Reinstatement to Official QuotationPRICE SENSITIVE02/05/17
EVE Voluntary SuspensionPRICE SENSITIVE27/03/17
EVE Trading HaltPRICE SENSITIVE23/03/17
EVE Omni Innovation - US Patent Notice of Allowance ReceivedPRICE SENSITIVE01/03/17
EVE Half Yearly Report and AccountsPRICE SENSITIVE28/02/17
EVE Appendix 4C - QuarterlyPRICE SENSITIVE30/01/17
EVE Sales Results Exceed Expectations for Faulding GlucoControlPRICE SENSITIVE25/01/17
EVE RGP: Refresh Invests in Technology CompanyPRICE SENSITIVE28/12/16
EVE ProspectusPRICE SENSITIVE23/12/16
EVE Reinstatement to Official QuotationPRICE SENSITIVE23/12/16
EVE $1.6m Placement for Omni Innovation InvestmentPRICE SENSITIVE23/12/16
EVE Suspension from Official QuotationPRICE SENSITIVE14/12/16
EVE Trading HaltPRICE SENSITIVE12/12/16
EVE Notification of Rights Issue ShortfallPRICE SENSITIVE09/12/16
EVE Omni Innovation Market UpdatePRICE SENSITIVE02/12/16
EVE Omni Innovation secures UK Distribution DealPRICE SENSITIVE21/11/16
EVE Non-Renounceable Rights OfferPRICE SENSITIVE16/11/16
EVE Reinstatement to Official QuotationPRICE SENSITIVE10/11/16
EVE Placement to Chinese Pharmaceutical and Investment GroupPRICE SENSITIVE10/11/16
EVE Voluntary Suspension-EVE.AX PRICE SENSITIVE03/11/16
EVE Voluntary SuspensionPRICE SENSITIVE03/11/16
EVE Trading Halt-EVE.AX PRICE SENSITIVE01/11/16
EVE Appendix 4C - Quarterly-EVE.AX PRICE SENSITIVE01/11/16
EVE New Study- GlucoControl Improves Long-Term Glycaemic Control-EVE.AX PRICE SENSITIVE21/09/16
EVE Appendix 4E and Full Year Statutory Accounts-EVE.AX PRICE SENSITIVE01/09/16
EVE Omniblend Innovation Enters into US Representation Deal-EVE.AX PRICE SENSITIVE24/08/16
EVE Appendix 4C - Quarterly-EVE.AX PRICE SENSITIVE27/07/16
EVE GlucoControl Momentum-EVE.AX PRICE SENSITIVE05/07/16
EVE GlucoControl Pre-Meal Drink Launched-EVE.AX PRICE SENSITIVE06/05/16
EVE Appendix 4C - Quarterly-EVE.AX PRICE SENSITIVE26/04/16
EVE Extension of Omniblend Innovation Tranche 2 SettlementPRICE SENSITIVE01/04/16
EVE Half Yearly Report and AccountsPRICE SENSITIVE01/03/16
EVE GlucoControl Product Manufacturing CommencesPRICE SENSITIVE25/02/16
EVE ProspectusPRICE SENSITIVE18/02/16
EVE Fully Underwritten Rights IssuePRICE SENSITIVE18/02/16
EVE Appendix 4C - QuarterlyPRICE SENSITIVE29/01/16
EVE EVE Investments makes first medical technology investmentPRICE SENSITIVE17/12/15
EVE Trading HaltPRICE SENSITIVE15/12/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE20/10/15
EVE ProspectusPRICE SENSITIVE19/10/15
EVE Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE28/08/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE30/07/15
EVE PlacementPRICE SENSITIVE29/06/15
EVE Trading HaltPRICE SENSITIVE25/06/15
EVE Company UpdatePRICE SENSITIVE24/06/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE27/04/15
EVE Half Yearly Report and AccountsPRICE SENSITIVE27/02/15
EVE Company UpdatePRICE SENSITIVE27/02/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE28/01/15
EVE Placement
26/03/19PRICE SENSITIVE
EVE Meluka Honey Appoints OpenDNA for Chinese Market Entry
12/03/19PRICE SENSITIVE
EVE Appendix 4D and Half Year Report
01/03/19PRICE SENSITIVE
EVE EVE to Acquire Remaining 50% of Meluka Health
25/02/19PRICE SENSITIVE
EVE Response to ASX Appendix 4C Query
19/02/19PRICE SENSITIVE
EVE Quarterly Review
31/01/19PRICE SENSITIVE
EVE Meluka Honey Secures Distribution for NSW & ACT
14/11/18PRICE SENSITIVE
EVE Meluka Honey Combines Anti-Microbial & Anti-Oxidant Activity
08/11/18PRICE SENSITIVE
EVE Quarterly Review
25/10/18PRICE SENSITIVE
EVE Appendix 4E and Full Year Statutory Accounts
31/08/18PRICE SENSITIVE
EVE Prospectus
30/08/18PRICE SENSITIVE
EVE Quarterly Review
25/07/18PRICE SENSITIVE
EVE Completion of THC Agreements
24/07/18PRICE SENSITIVE
EVE Omni Innovation - Update by Eagle Health on Chinese Market
16/07/18PRICE SENSITIVE
EVE Update on THC Agreements
03/07/18PRICE SENSITIVE
EVE EVE to Acquire Leading Aust Organic Tea Tree Oil Producer
21/06/18PRICE SENSITIVE
EVE Trading Halt
19/06/18PRICE SENSITIVE
EVE THC: Secures Additional Site for Medicinal Cannabis Growth
03/05/18PRICE SENSITIVE
EVE Quarterly Review
30/04/18PRICE SENSITIVE
EVE First Quarter China Sales Progress
26/04/18PRICE SENSITIVE
EVE Half Yearly Report and Accounts
26/02/18PRICE SENSITIVE
EVE Meluka Consumer Products Launch at US Natural Products Expo
23/02/18PRICE SENSITIVE
EVE Rights Issue Offer Document
19/02/18PRICE SENSITIVE
EVE Prospectus
06/02/18PRICE SENSITIVE
EVE Quarterly Review
31/01/18PRICE SENSITIVE
EVE Oversubscribed Placement & Rights Issue to Raise up to $6.3m
31/01/18PRICE SENSITIVE
EVE Trading Halt
25/01/18PRICE SENSITIVE
EVE Eagle Begins Shipment of Omni Innovation's Diabetes Product
08/12/17PRICE SENSITIVE
EVE Meluka Health to Develop Honey Water for Chinese Market
07/12/17PRICE SENSITIVE
EVE Eve Completes 50% Investment in Meluka Health
06/12/17PRICE SENSITIVE
EVE Response to ASX Price & Volume Query
30/11/17PRICE SENSITIVE
EVE NSW Grant for Honey Research Successful
27/11/17PRICE SENSITIVE
EVE Prospectus
22/11/17PRICE SENSITIVE
EVE Medic Honey Produces a Hemp Seed Honey
22/11/17PRICE SENSITIVE
EVE Supply Agmt with Large Producer of Australian Organic Honey
06/11/17PRICE SENSITIVE
EVE Eagle Commences Production of Omni's Pre-Meal Diabetes Shake
31/10/17PRICE SENSITIVE
EVE Appendix 4C - Quarterly
20/10/17PRICE SENSITIVE
EVE Prospectus
13/10/17PRICE SENSITIVE
EVE Reinstatement to Official Quotation
06/10/17PRICE SENSITIVE
EVE $1.2m Capital Raising
06/10/17PRICE SENSITIVE
EVE Voluntary Suspension
27/09/17PRICE SENSITIVE
EVE Trading Halt
25/09/17PRICE SENSITIVE
EVE Appendix 4E and Full Year Statutory Accounts
01/09/17PRICE SENSITIVE
EVE Revised Medical Honey Investment Structure
28/08/17PRICE SENSITIVE
EVE Omni Innovation Enters Chinese Distribution Agreement
16/08/17PRICE SENSITIVE
EVE Trading Halt
14/08/17PRICE SENSITIVE
EVE Appendix 4C - Quarterly
31/07/17PRICE SENSITIVE
EVE Prospectus
04/07/17PRICE SENSITIVE
EVE Accelerating Portfolio Progress
26/06/17PRICE SENSITIVE
EVE Southern Cross University Collaboration with Medic Honey
30/05/17PRICE SENSITIVE
EVE Prospectus
05/05/17PRICE SENSITIVE
EVE Reinstatement to Official Quotation
02/05/17PRICE SENSITIVE
EVE Voluntary Suspension
27/03/17PRICE SENSITIVE
EVE Trading Halt
23/03/17PRICE SENSITIVE
EVE Omni Innovation - US Patent Notice of Allowance Received
01/03/17PRICE SENSITIVE
EVE Half Yearly Report and Accounts
28/02/17PRICE SENSITIVE
EVE Appendix 4C - Quarterly
30/01/17PRICE SENSITIVE
EVE Sales Results Exceed Expectations for Faulding GlucoControl
25/01/17PRICE SENSITIVE
EVE RGP: Refresh Invests in Technology Company
28/12/16PRICE SENSITIVE
EVE Prospectus
23/12/16PRICE SENSITIVE
EVE Reinstatement to Official Quotation
23/12/16PRICE SENSITIVE
EVE $1.6m Placement for Omni Innovation Investment
23/12/16PRICE SENSITIVE
EVE Suspension from Official Quotation
14/12/16PRICE SENSITIVE
EVE Trading Halt
12/12/16PRICE SENSITIVE
EVE Notification of Rights Issue Shortfall
09/12/16PRICE SENSITIVE
EVE Omni Innovation Market Update
02/12/16PRICE SENSITIVE
EVE Omni Innovation secures UK Distribution Deal
21/11/16PRICE SENSITIVE
EVE Non-Renounceable Rights Offer
16/11/16PRICE SENSITIVE
EVE Reinstatement to Official Quotation
10/11/16PRICE SENSITIVE
EVE Placement to Chinese Pharmaceutical and Investment Group
10/11/16PRICE SENSITIVE
EVE Voluntary Suspension-EVE.AX
03/11/16PRICE SENSITIVE
EVE Voluntary Suspension
03/11/16PRICE SENSITIVE
EVE Trading Halt-EVE.AX
01/11/16PRICE SENSITIVE
EVE Appendix 4C - Quarterly-EVE.AX
01/11/16PRICE SENSITIVE
EVE New Study- GlucoControl Improves Long-Term Glycaemic Control-EVE.AX
21/09/16PRICE SENSITIVE
EVE Appendix 4E and Full Year Statutory Accounts-EVE.AX
01/09/16PRICE SENSITIVE
EVE Omniblend Innovation Enters into US Representation Deal-EVE.AX
24/08/16PRICE SENSITIVE
EVE Appendix 4C - Quarterly-EVE.AX
27/07/16PRICE SENSITIVE
EVE GlucoControl Momentum-EVE.AX
05/07/16PRICE SENSITIVE
EVE GlucoControl Pre-Meal Drink Launched-EVE.AX
06/05/16PRICE SENSITIVE
EVE Appendix 4C - Quarterly-EVE.AX
26/04/16PRICE SENSITIVE
EVE Extension of Omniblend Innovation Tranche 2 Settlement
01/04/16PRICE SENSITIVE
EVE Half Yearly Report and Accounts
01/03/16PRICE SENSITIVE
EVE GlucoControl Product Manufacturing Commences
25/02/16PRICE SENSITIVE
EVE Prospectus
18/02/16PRICE SENSITIVE
EVE Fully Underwritten Rights Issue
18/02/16PRICE SENSITIVE
EVE Appendix 4C - Quarterly
29/01/16PRICE SENSITIVE
EVE EVE Investments makes first medical technology investment
17/12/15PRICE SENSITIVE
EVE Trading Halt
15/12/15PRICE SENSITIVE
EVE Appendix 4C - Quarterly
20/10/15PRICE SENSITIVE
EVE Prospectus
19/10/15PRICE SENSITIVE
EVE Appendix 4E and Full Year Statutory Accounts
28/08/15PRICE SENSITIVE
EVE Appendix 4C - Quarterly
30/07/15PRICE SENSITIVE
EVE Placement
29/06/15PRICE SENSITIVE
EVE Trading Halt
25/06/15PRICE SENSITIVE
EVE Company Update
24/06/15PRICE SENSITIVE
EVE Appendix 4C - Quarterly
27/04/15PRICE SENSITIVE
EVE Half Yearly Report and Accounts
27/02/15PRICE SENSITIVE
EVE Company Update
27/02/15PRICE SENSITIVE
EVE Appendix 4C - Quarterly
28/01/15PRICE SENSITIVE
(20min delay)
Last
0.1¢
Change
0.000(0.00%)
Mkt cap ! $5.274M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
EVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.